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Diabetes occurs more often in individuals with COPD than in the general population, however there are still many
issues that need to be clarified about this association. The exact prevalence of the association between diabetes
and COPD varies between studies reported, however it is known that diabetes affects 2–37 % of patients with
COPD, underlining the need to better understand the link between these two conditions. In this review, we
evaluated the epidemiological aspects of the association between diabetes and COPD analyzing potential common
issues in the pathological mechanisms underlying the single disease. The close association suggests the occurrence
of similar pathophysiological process that leads to the development of overt disease in the presence of conditions
such as systemic inflammation, oxidative stress, hypoxemia or hyperglycemia. Another, but not less important,
aspect to consider is that related to the influence of the pharmacological treatment used both for the patient
affected by COPD and from that affected by diabetes. It is necessary to understand whether the treatment of COPD
affect the clinical course of diabetes, it is also essential to learn whether treatment for diabetes can alter the natural
history of COPD.
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Diabetes mellitus (DM) is a common comorbidity of
chronic obstructive pulmonary disease (COPD) [1]. A
series of studies have shown that DM is associated with
impaired lung function [2]. The chronic complications
of diabetes include a number of pathological changes in-
volving different districts and, among these, lung repre-
sents a target organ for diabetic microangiopathy in
patients with diabetes [3]. The Framingham Heart Study
has reported an association between glycemic status and
reduced lung function [4]. The diagnosis of DM was as-
sociated with lower adjusted mean residual forced ex-
piratory volume in one second (FEV1) and Forced vital
capacity (FVC). The Copenhagen City Heart Study, a
longitudinal analysis [5], has shown an association be-
tween a new diagnosis of diabetes and impaired lung
function that was more prominent in diabetic subjects
treated with insulin compared with subjects treated with
oral hypoglycaemic agents. In a prospective Australian
study, the Fremantle Diabetes Study, 125 patients with* Correspondence: paola.rogliani@uniroma2.it
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disease was assessed by spirometry at baseline and reval-
uated seven years later. The key finding was that the
average rate of decline in lung function, as measured by
FEV1 was 71 ml/year compared to an expected decline
in healthy non-smokers of 25–30 ml/year, suggesting
that the exposure to blood glucose may be a strong and
consistent negative predictor of lung function follow-up
after adjustment for baseline and potential confounders
[6]. The association between impaired lung function and
diabetes is thought to be the result of biochemical
changes in the structures of the lung tissue and airways
that involves a series of mechanisms likely due to sys-
temic inflammation, oxidative stress, hypoxemia or ul-
timately to the direct damage caused by chronic
hyperglycemia. The lung function decline in patients
with diabetes may be a consequence of diabetes itself
and diabetic patients seem to have an increased risk of
several non-neoplastic lung conditions such as asthma
and COPD [3].
In a retrospective study using data collected from the
Italian College of General Practitioners Health Search
Database it was reported that compared to the non-article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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prevalence of DM (10.5 % in the general population vs.
18.7 % in patients with COPD) [7, 8]. This data has
been confirmed in another study conducted in Taiwan
that reported in COPD patients a higher risk of T2D
compared with control subjects after adjusting for con-
founding factors [9]. However, there are also contrast-
ing data in the literature, such as those reported by
Korean researchers who have found no association be-
tween COPD and DM perhaps due to differences in
race or nutritional factor; or probably simply due to a
misclassification when general practitioners use specific
diagnostic categories, mainly COPD [10].
In any case, it is not known why patients with COPD
are affected by T2D more often than non-T2D subjects.
Many conditions, in addition to chronic hyperglycemia,
such as inflammation or disease-related inflammation,
oxidative stress, hypoxia, reduced physical activity, and
smoking habit may contribute to the higher prevalence
of diabetes in COPD. In addition to all these condi-
tions, the treatment with corticosteroids is considered




Diabetes occurs more often in people with COPD than
in the general population [11], although the exact preva-
lence varies between studies.
A retrospective analysis examined the relationship be-
tween COPD and comorbidities using Health Search
Database information obtained from Italian College ofTable 1 Summary of epidemiological study
COPD risk of T2D Population studied
Prospective cohort study
with a mean follow up of
20.9 years
n:1,050 men (with no self-reported DM
in the final analysis mean age: 41.4 yea
BMI: 25.6 kg/m2
Prospective cohort study
with a mean follow up of
13 years
n: 382 non-diabetic men BMI: 24.4–24.7
(depends on the pulmonary VC subgro
Prospective cohort study
with a follow up of 5 years
n: 9,220 men non-diabetic at baseline m
41.4 years mean baseline BMI: 24.4 kg/m
patients without type 2 DM at follow u
26.7 kg/m2 for patients with type 2 DM
follow up
Prospective cohort study. From
1988 to 1996
data from the Nurses’ Health Study from
1988 to 1996 which enrolled 103,614 fe
Prospective study of
middle-aged and older US
women followed over 12 years
38,570 women who were aged≥ 45 ye
of cardiovascular disease and cancer at
and free of diabetes at baseline
Cohort from the Genetic
Epidemiology of COPD Study
(COPDGene)
smokers with and without COPD at 21
centers throughout the United States B
2007– 2011General Practitioners, that stores information of nearly
1.5 % of the national population. Compared to the non-
COPD individuals, COPD patients were at increased risk
of DM, 10.5 % in the general population vs. 18.7 % in
COPD patients. Unexpectedly, in this study COPD pa-
tients had an increased prevalence of both cardiovascu-
lar diseases and T2D and a very low prevalence of the
metabolic syndrome, suggesting that COPD is a real risk
factor for cardiovascular diseases and diabetes [8].
It has been consistently reported (Table 1) an im-
paired pulmonary function and glucose intolerance in
several cross-sectional and perspective studies. A pro-
spective study conducted in a five years observation
period reported that the development of DM was asso-
ciated with greater rates of decline of pulmonary func-
tion suggesting that diabetes may be, in particular at its
onset, is associated with a significantly accelerated de-
cline of respiratory function [12]. Lazarus et al within
the Normative Aging Study in their perspective analysis
reported that FVC was negatively associated with the
risk to have higher levels of insulin resistance and a
similar associations were found for FEV1 and maximal
mid-expiratory flow rate (MMEF), suggesting the possi-
bility that insulin resistance could be the factor corre-
lated with the impairment of pulmonary function [13].
In another prospective study with a median follow up
of 13 years, the authors concluded that the risk of de-
veloping diabetes is inversely associated with pulmon-
ary function and the longitudinal associations between
vital capacity (VC) and diabetes (P = 0.001) and log glu-




Reduced FVC, FEV1 and MMEF were associated
with greater fasting insulin and fasting insulin





15 new cases of DM 2 were diagnosed during the
follow up. DM and glucose were inversely







207 patients developed T2D with the incidence of
2.2 %. FEV1 and FVC were negatively associated
with T2D. In patients with BMI < 25 kg/m2 the
lowest quartile of FVC and FEV1 had OR of 2.15





COPD was found to have a multivariate RR of 1.8





The presence of COPD was associated with an
approximately 1.50-fold increased risk of T2D






Non-emphysematous COPD, defined by airflow
obstruction with a paucity of emphysema on
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during the 8 years follow-up found that the risk to have
T2D was significantly higher in patients with COPD
than those without COPD (multivariate relative risk 1.8,
95 % CI 1.1–2.8) nor those with asthma. These data sug-
gest that COPD could be a risk factor for developing
T2D, perhaps sharing common inflammatory and cyto-
kine profile [15]. In another Korean study, planned to
assess the relationship between lung function and inci-
dent T2D, 9,220 men without T2D were prospectively
followed for five years. The authors found that impaired
lung function is independently associated with the inci-
dence of T2D. FVC and FEV1 were negatively associated
with T2D (P < 0.05) independently by confounding fac-
tors. It is therefore proposed on the basis of these re-
sults, the possibility that the reduced lung function, as
measured by FEV1 and FVC, may precede the develop-
ment of T2D [16].
Differently, in a prospective study conducted in a co-
hort of 38,570 women with median follow-up of 12.2
years, the hypothesis that asthma or COPD could be in-
volved in the pathogenesis of T2D was tested. Both
asthma and COPD were individually and independently
associated with an increased risk of T2D in women; this
association was independent of cigarette smoking and
other diabetes risk factors and also persisted after ex-
cluding all COPD cases with asthmatic symptoms. The
multivariate RRs were 1.38 (95 % CI, 1.14–1.67) for COPD
without asthmatic symptoms [17].
Recently, an increased prevalence of diabetes in
non-emphysematous COPD patients (diabetes OR
2.13, p < 0.0001) has been reported in the COPD Gene
Study, where patients were classified in emphysema-
predominant and non-emphysematous COPD based
on CT scan features [18]. Although comorbidities were
self-reported, previous studies have shown that it is a
reliable source of information [19]. This association
persisted also after performing stratified analyses con-
sidering obese and non-obese individuals, smoking
habit, bronchial obstruction severity divided in GOLD
1– 2 and GOLD 3– 4, ethnicity and age. These results
were also confirmed by the ECLIPSE study, where dia-
betes was reported in 10.6 % of non-emphysema and
in 8.2 % of emphysema-predominant COPD [20]. The
authors suggested to evaluate for diabetes patients with
COPD, especially those defined non-emphysema [18].
In a study conducted in UK using the wide primary
care data to quantify the burden of comorbidity among
individuals with COPD, it has been shown that COPD is
associated with an increased odds of DM. Intriguingly
the effect of COPD having DM is higher in current
smokers for the younger patients, but after the age of 45
becomes greater in non-smokers, suggesting that this as-
sociation was independent of smoking status [21].Mechanisms
DM is a common comorbidity of COPD [7]. What are
the mechanisms underlying the increased prevalence of
diabetes in COPD still remains unclear, although a num-
ber of potential pathways including inflammation, oxida-
tive stress, hypoxia and chronic hyperglycemia may
provide some explanation [11, 2].
Systemic inflammation is a common feature to both
COPD and to T2D, which drives insulin resistance, ath-
erosclerosis and many systemic expressions of COPD it-
self. The presence of systemic inflammation is poorly
defined in patients with COPD. Most of the studies were
cross-sectional and show that not all patients with
COPD have a systemic inflammatory response. However
systemic inflammation is a risk factor for the develop-
ment of many chronic diseases, which are COPD co-
morbidity [22]. However, we should consider that the
persistent systemic inflammation in COPD patients is
associated with significantly worse outcomes in terms of
mortality and exacerbation rate as demonstrated by the
ECLIPSE study. It appears to be mostly independent
from the pulmonary component of the disease, raising
the possibility that systemic inflammation could be a
possible therapeutic target in these patients [23]. The
possible development of COPD and T2D could have evi-
dence in the context of a chronic systemic inflammation
with the presence of cardiovascular disease or metabolic
disorders, known to be related to systemic inflammation,
increasing the association between COPD and DM [7].
In any case, systemic inflammation might be increased
by the coexistence of these two conditions, COPD and
diabetes, worsening both in their clinical manifestations.
There are many evidences that the levels of inflamma-
tory proteins (Table 2), such as cytokines and among
these TNF- α, IL-6, or C reactive protein (CRP), are in-
creased in patients with COPD. Systemic inflammation
is associated with various complications in COPD, in-
cluding cardiovascular and metabolic diseases such as
diabetes.
TNF-α is a marker of systemic inflammation that ap-
pears to be associated with the severity of COPD, in-
creased levels are seen in severe and very severe COPD.
On the other hand, high levels of TNF- α may be a risk
factor for the development of new-onset T2D, interfering
with glucose metabolism and insulin sensitivity [22, 24],
suggesting a possible link between COPD and T2D.
Increased levels of IL-6 are independently associated
with COPD, in particular serum concentrations of this
cytokine were found significantly increased in COPD ex-
acerbation compared to patients in stable phase [25].
Furthermore, IL-6 is a potent stimulator of CRP pro-
duction by the liver and the increase of CRP that is ob-
served in patients with COPD could represent an
explanation. CRP serum is considered the biomarker of
Table 2 Potential mediators involved in the higher prevalence of T2D in COPD
COPD DM Ref
CRP COPD is independently associated with increased
levels of CRP. Moreover, CRP may predict the future
onset of COPD.
Elevated CRP levels may predict the development
of onset of T2D.
[24]
TNF-α COPD is independently associated with increased
levels of TNF-α. activates NF-kB leading to cytokine
production, upregulation of adhesion molecules and
increasing oxidative stress
May be a risk factor for the development of new
onset T2D. May interfere with glucose metabolism
and insulin sensitivity, and can be antagonized by
adiponectin which reduces NfkB activation.
[24]
IL-1 IL-1 is implicated in the pathogenesis of COPD related
inflammation.
An increase in IL-1β may predict the development
of new onset T2D.
[24]
IL-6 COPD is independently associated with increased
levels of IL-6. This cytokine is a potent stimulator of
CRP production by the liver and may account for the
increase in circulating CRP found in patients with COPD.
IL-6 was shown to increase the risk for the new
onset T2D.
[24]
Leptin Leptin levels are increased in patients with COPD.
May contribute to COPD related weight loss, PFT
decline and prolonged hospital stay. Leptin induced
IR and hyperglycemia
Leptin may increase the risk of T2D. Leptin may
participate in the development of DM related




Adiponectin Adiponectin levels are increased in patients with COPD
and low BMI, Increased adiponectin was related to a
decrease in cardiovascular mortality, but was associated
with an increase in mortality due to respiratory causes.
Adiponectin may prevent the development of T2D
via its anti-inflammatory and proinsulin actions.
[24, 79,
80]
Resistin Resistin levels may be increased in COPD and
mediate IR.
Resistin may directly participate in the development
of IR
[24]
Catecholamine patients with COPD had higher catecholamine levels
which were independently related to a decrease in
FEV1.
Insulin antagonists and contribute to the occurrence
of hyperglycemia. Abnormalities in the renin
angiotensin aldosterone system (RAAS) are implicated
in the development and pathogenesis of cardiovascular
diseases, Metabolic Syndrome and T2D
[81, 24,
82, 83]
NF-kB NF-kB activation is implicated in systemic inflammation and could
be involved in skeletal muscle dysfunction in COPD patients
NF-kB activation has also been associated with
Diabetes
[84, 85]
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inflammatory biomarkers including IL-6 [26, 27]. Many
are the associations that have been reported between
CRP and the different aspects of COPD. Studies that
have explored these aspects have shown contrasting
results: a meta-analysis showed a marked difference in
the level of serum CRP in COPD compared with con-
trols [28], while in another meta-analysis has not been
found any statistically significant difference in CRP
levels between COPD and control [29]. Though, a
population-based study showed that the increase in
CRP was observed in stable COPD compared with
controls, even after adjustment for potential con-
founders [26]. Furthermore cross-sectional studies
show that CRP is inversely associated with the FEV1
and PaO2 in patients with COPD [30, 24], confirming
the idea that there is a systemic inflammatory response
in this disease progressively debilitating [31]; in fact
both IL-6 and CRP have been shown to increase the
risk of developing new-onset T2D, especially the high
levels of CRP may predict the development of the on-
set of T2D [24].
Oxidative stress is generated by an imbalance between
oxidants and antioxidants. In COPD patients, either instable or during acute exacerbations, oxidative stress is
increased mainly by inhalation of oxidants such as those
generated by cigarette smoke or pollution, or as a result
of inflammatory leukocytes that are activated to release
reactive oxygen species. This condition can cause direct
damage to the lung targeting lipids and proteins, trigger-
ing specific pathways, which could generate increased
gene expression, production pro-inflammatory cytokines
and ultimately increased inflammation [32]. Finally adi-
ponectin, an adipokin with intrinsic anti-inflammatory
property, correlates with COPD; data obtained in case-
control studies demonstrated a higher systemic and air-
way adiponectin concentrations in COPD patients
mainly men than controls. Moreover serum adiponectin
has a positive correlation with lung function in healthy
adults, whereas an inverse correlation has been found in
studies conducted in male individuals with COPD [33].
In T2D oxidative stress is present through the activa-
tion of specific biochemical pathways, increased produc-
tion of reactive oxygen species, reduction of antioxidants
and furthermore increase lipid peroxidation. Oxidative
stress, mainly smoke-induced in COPD patients, could
cause in T2D the continuation of the insulin resistance
by altering the production of energy. Conversely
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COPD activating inflammation and even compromis-
ing the response to glucocorticoids [11].
Smoking induces oxidative stress that can trigger local
and systemic inflammation, though cigarette smoking is
not a link between DM and COPD [34]. This is espe-
cially interesting given that exposure to cigarette smok-
ing is crucial for the development of COPD [35] and, at
the same time, an independent and modifiable factor for
the development of DM [36]. Since cigarette smoking
does not appear to be the connection, it is likely that
other mechanisms besides systemic inflammation or oxi-
dative stress could define the link between DM and
COPD.
Current evidence suggests that COPD, in which hyp-
oxia is one of the typical features, is associated with in-
creased levels of oxidative stress [37], but likewise an
excessive oxidative stress may be a risk factor for new-
onset T2D it can be also a result of new onset DM [38].
Moreover, the induction of increased levels of reactive
oxygen species (ROS), NF-kB and intracellular mediators
of inflammation could also lead to chronic hypergly-
cemia and to an increased synthesis of collagen mediated
by higher levels of advanced glycation end products that
ultimately would affect negatively lung function [39].
Hypoxia causes significant changes in metabolism,
studies conducted in healthy subjects at high altitude
showed increased insulin resistance and glucose produc-
tion in the liver [40, 41] with greater insulin sensitivity at
peripheral level and increased uptake of glucose in
skeletal muscle [42]. It seems that pancreatic β cells
are sensitive to hypoxia-induced damage, regardless of
the condition of intermittent hypoxia as that observed
in sleep apnea [43], or chronic hypoxia seen in COPD.
Indeed, chronic hypoxia has been observed in associ-
ation with impaired glucose tolerance, reduced insulin
sensitivity accompanied by greater lipolysis. In COPD
patients, in which the normalization of saturation
values has been obtained, it can be observed an im-
provements of glucose tolerance and insulin sensitivity
[44, 45]. It is possible that both of these diseases,
COPD and DM, might share common pathophysio-
logical pathways which can be mediated by hypoxia in-
ducible factor (HIF) [46].
Inflammation, oxidative stress and hyperglycemia in
particular, have been shown to induce muscle dysfunc-
tion [47]. Lower lung function has also been suggested
to be associated with increased serum osmolarity, where
blood sugar contributes to the total serum osmolarity
[48, 13]. A number of prospective studies have shown
that reduced lung function is an independent predictor
of T2D [13, 14, 49]. In particular, in a prospective study
on lung function in adults with T2D, it has been suggested
the idea that alterations in lung function may precedediabetes and then will progress after the onset of dia-
betes itself [50].
In a study that we conducted on isolated human bron-
chi, we found that high glucose concentrations lead to
enhanced responsiveness of airway smooth muscle cells
to contractile agent. The data suggested that the glucose-
induced enhancement of bronchial responsiveness is likely
to be due to increased activation of a particular intracellu-
lar pathway: the Rho-kinase pathway. It seems that the
Rho/ROCK pathway plays a role in regulating several bio-
logical pathways, including some that affect the level of
airway smooth muscle (ASM) tone [2]. The activation of
this pathway mediates multiple biological functions in-
volving contractility based on actin-myosin [51]. More-
over, our results suggested that the Rho/ROCK pathway,
together with the mobilization of the intracellular calcium
and the phosphorylation of MYPT-1, might play a crucial
role in the reduced lung function observed in patients
with diabetes [2]. It is widely accepted that airway hyper-
responsiveness is a risk factor for an accelerated decline in
FEV1 and the development of obstructive pulmonary dis-
ease such as COPD [50]. As well as pulmonary function
impairment that is greater in patients with poorly con-
trolled diabetes, a finding that, however, is not explained
by obesity or increasing age [7].
Treatment
The strong association between COPD and diabetes has
been explained through evaluation of probable common
risk factors, or probable common mechanisms, but it was
also explained as a potential consequence of treatment op-
tions for COPD. Corticosteroids is considered the main
therapeutic approach potentially implicated in the strong
association between diabetes and COPD. The use of corti-
costeroids, in susceptible individuals, may determine
states of hyperglycemia. In fact, the use of inhaled cortico-
steroid (ICS) has been reported to be correlated with an
increase in the concentration of plasma glucose in diabetic
patients, and this increase seems to be modulated in a
dose-response manner [52]. Short-term treatment with
oral corticosteroids, used in acute exacerbations, is associ-
ated with a five-fold increased risk of acute hyperglycemia
and also the long-term use of oral corticosteroids in stable
COPD is correlated with increased risk of glucose intoler-
ance [53, 54]. Studies evaluating the actual impact of ICSs
on the association between these two pathological condi-
tions, and if ICSs actually increase the risk of DM, have
shown contrasting results [18]. In a prospective, crossover
study, patients with T2D exhibited small but statistically
significant increased glycosylated hemoglobin levels after
6 weeks of treatment with an ICS, fluticasone, although
this did not have a clinically significant impact on long-
term glycaemic control [55]. Instead, in a more recent
retrospective study, double-blind, placebo-controlled,
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budesonide/ formoterol in COPD highlighted that the
treatment with ICS in COPD patients was not associated
with an increased risk of new-onset DM nor hypergly-
cemia [56]. These studies outline how the association be-
tween COPD and T2D might be independent of the use of
ICSs [56], although the discrepancy of reported data leave
doubts about the real influence of ICSs on diabetes [57].
Beyond everything, it should not be precluded the use
of ICSs in COPD patients, where clinical evidence sug-
gests that they may be useful, rather it should be aware
that there is a risk of unwanted side effects and it should
be considered a use of the lowest possible dose to obtain
the optimal management of the disease [57].
Another class of anti-inflammatory treatment is avail-
able for severe COPD associated with chronic bronchitis
and a history of frequent exacerbations: the phospho-
diesterase 4 (PDE4) inhibitor. This treatment has been
shown to be related to weight decreased transient and re-
versible, suggesting a systemic role of this drug possibly
impacting on metabolism [58]. In a small randomized,
double-blind, placebo-controlled study the effects of a
PDE4 inhibitor on the glucose homeostasis and body
weight in newly diagnosed T2D without COPD was inves-
tigated. Glycated hemoglobin levels and change from
baseline in the postmeal for several metabolic parameters
were the main outcomes. In patients with T2D a signifi-
cant reduction in glycated hemoglobin (least square mean:
0.45 %; P: 0.0001) was observed as well as the postmeal
rise in glucagon and fasting plasma glucose levels that was
lower in the PDE4 inhibitor treatment group compared
with in placebo group, suggesting that this antiflammatory
drug could help to reduce the postprandial hyperglycemia
that characterizes T2D state. The authors concluded that
PDE4 inhibitors can lower glucose levels in patients with
newly diagnosed T2D without COPD, although the exact
mechanism is still unknown [59].
As far as regarding the other class of drugs for the
mainstay treatment of COPD, for inhaled bronchodila-
tors there are not much evidences on the association
between COPD and diabetes. In a pooled analysis from
19 randomized, doubleblind, placebo-controlled trials
with a longacting anticholinergic bronchodilator tiotro-
pium, safety showed that there was no apparent in-
creased risk of DM (RR, 0.99; 95 % CI, 0.41 to 2.37), in
patients receiving tiotropium compared to those re-
ceiving placebo, however the relative risk of hypergly-
cemic events was 1.69 [60].
In patients with T2D, metformin is the recommended
first-line treatment [61], and this treatment is associated
with reduce risk of cardiovascular events and death [62].
Metformin has been, although rarely, associated with
lactic acidosis which may be fatal, thus its safety in
COPD it has been questioned [63]. The British NationalFormulary and the US Federal Drug Administration sug-
gested that metformin should be discontinued immedi-
ately in any conditions associated with hypoxemia.
Hence, the clinical use of metformin in patients with
diabetes and coexisting COPD is limited whether it is
appropriate or not [64]. Metformin, thanks to its pleio-
tropic anti-inflammatory and antioxidants actions [65,
66], may have a role in COPD by limiting glucose flux
through the epithelium of the airways that is associated
also with respiratory infections [67]. A retrospective
study, which included patients with COPD and DM,
showed that treatment with oral hypoglycemic agents
was independently associated with the improvement of
FVC [68]. Moreover, a recent open-label study where
metformin in patients with COPD has been used, sug-
gested that this drug could improve respiratory muscle
strength [69]. Safety of metformin in COPD has been
evaluated in a recent retrospective cohort. COPD pa-
tients treated with metformin showed an association
with lower elevation of lactate concentration of uncer-
tain clinical significance [64]. The authors are currently
recruiting patients in the UK in a prospective clinical
trial, in order to clarify the use of metformin in COPD
(Current Controlled Trials ISRCTN66148745).
Although the Copenhagen City Heart Study has shown
an association between a new diagnosis of DM and im-
paired lung function, a condition that was more promin-
ent in diabetic subjects treated with insulin rather than
those treated with oral hypoglycaemic agents [5], insulin
may play a role in facilitation of the alveolar-capillary
interface conductance [70].
T2D seems to be associated with the reduction of al-
veolar microvascular reserves and possibly be evidence
of deterioration in lung volume, alveolar perfusion and
capillary recruitment. This reduction correlates with gly-
cemic control and extrapulmonary microangiopathy [71].
Lung diffusing capacity for carbon monoxide (DLCO) is a
known surrogate marker for the alveolar capillary mem-
brane morphological and functional status. A small study
on diabetic patients tested the effects of regular insulin on
DLCO: insulin improved DLCO in patients with T2D pos-
sibly through a facilitation of the alveolar-capillary inter-
face conductance [70]. Based on possible role of insulin in
improving pulmonary gas exchange it was attempted in-
haled use. However, the use of inhaled insulin has
highlighted potential negative effects and among them the
presence of cough, and potential reduction in DLCO and
FEV1 [72]. More research is needed before inhaled insulin
may be recommended in diabetic patients with or without
pulmonary disease.
Conclusions
The association between two complex conditions such
as COPD and T2D is expressed at different levels:
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anisms and the impact that the treatments used for indi-
vidual conditions may have on the association itself.
The complexity of this association also stems from the
evidence that COPD can be considered a risk factor for
the development of T2D, as pointed out by several epi-
demiological studies that have used national and inter-
national databases [8–10, 13].
In our opinion, the lung function may be affected in
conditions that precede the onset of T2D, such as in in-
dividuals with impaired glucose tolerance or in patients
with metabolic syndrome. If this hypothesis is correct,
we might state that pulmonary dysfunction precede the
onset of T2D, presenting similarities to the pathogenesis
of endothelial dysfunction that also usually develops be-
fore the onset of T2D, further studies need to be done
to clarify this aspect. This close association can lead to
the hypothesis that in a part of the population with
COPD and with T2D it would be possible to have a simi-
lar pathophysiological process that leads to the develop-
ment of overt disease in the presence of hyperglycemia
and/or respiratory failure. Recently, it has been reported
that a pro-inflammatory state, that could be a common
pathophysiological process for these two conditions, is
present in overweight or obese pre-diabetic individuals
and early stage of COPD [11]. Indeed, CRP, IL-6 and
TNF-α may contribute to an altered metabolic state and
insulin resistance. Furthermore, TNF-α is also a key in-
flammatory mediator in the process of muscle wasting,
sometimes associated with cachexia, and this reduces
peripheral insulin resistance in skeletal muscle [73]. On
the other side, a decrease in adiponectin levels, which
usually is present in pre-diabetic conditions, can contrib-
utes to the pulmonary and vascular damage [74]. Even-
tually, it is also possible that COPD may increase the
levels of oxidative stress due to a hypoxic state. In this
new scenario, COPD can also be considered a metabolic
disease with a pathophysiological process similar to
T2D. Hence, in this review we have addressed the differ-
ent aspects of this association, assessing in particular
among the hypothesized pathogenetic mechanisms in-
volved the possibility of a new concept of pathogenetic
link between COPD and T2D: hyperglycemia. Despite
the many data reported in the literature outlining how
hyperglycemia and higher levels of insulin-resistance
may be associated with the onset and progression of
these two conditions, the novelty is that glucose may dir-
ectly modulate bronchial tone. In fact glucose can dir-
ectly affect pulmonary bronchial tone and ASM through
the regulation of different molecular pathways in smooth
muscle cells. Indeed, we demonstrated as higher activation
of Rho/ROCK pathway can be a molecular pathway affect-
ing the pulmonary physiology associated to COPD in T2D
patients and the modulation of these substrates canpotentially represent a novel therapeutic target for the
treatment of COPD [2], although this finding should be
further explored.
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